By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ArQule, Inc. 

19 Presidential Way

Woburn  Massachusetts  01801  U.S.A.
Phone: 781-994-0300 Fax: 781-376-6019


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Discovery

Collaborations

Roche 

Pfizer 

Daiichi Sankyo, Inc. 





Company News
ArQule (ARQL) To Report Second Quarter 2017 Financial Results On August 4, 2017 7/21/2017 7:48:26 AM
ArQule (ARQL) Announces First Patient Dosed In Phase I Trial Of BTK Inhibitor, ARQ 531, For B-Cell Malignancies 7/11/2017 6:44:19 AM
ArQule (ARQL) Presents Preclinical Data For BTK Inhibitor, ARQ 531, At The 22nd Annual Congress Of European Hematology Association 6/23/2017 6:43:46 AM
ArQule (ARQL) Announces First Patient Dosed In Company Sponsored Phase I/II Trial Of AKT Inhibitor, ARQ 092, For Rare Overgrowth Diseases 6/7/2017 8:23:40 AM
ArQule (ARQL) Presents Phase 1/2 Clinical Data With ARQ 087 In Intrahepatic Cholangiocarcinoma At The 2017 ASCO Annual Meeting 6/5/2017 11:22:04 AM
ArQule (ARQL) To Present Clinical Data At The 2017 ASCO Annual Meeting 5/18/2017 8:34:54 AM
ArQule (ARQL) To Present Preclinical Data For BTK Inhibitor, ARQ 531, At The 22nd Annual Congress Of European Hematology Association 5/18/2017 8:09:04 AM
ArQule (ARQL) Reports First Quarter 2017 Financial Results 5/3/2017 6:37:55 AM
ArQule (ARQL) Announces Issuance Of U.S. Patent Covering Composition Of Matter Of Proprietary Reversible BTK Inhibitor, ARQ 531 4/26/2017 6:15:16 AM
ArQule (ARQL) To Report First Quarter 2017 Financial Results On May 3, 2017 4/19/2017 6:12:26 AM
12345678910...
//-->